COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al.

Gianfrancesco, Milena; Hyrich, Kimme L; Yazdany, Jinoos; Machado, Pedro M; Robinson, Philip C

COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al.

Gianfrancesco, Milena; Hyrich, Kimme L; Yazdany, Jinoos; Machado, Pedro M; Robinson, Philip C.

Afiliação

Gianfrancesco M; Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, California, USA.
Hyrich KL; Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK.
Yazdany J; Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, California, USA.
Machado PM; MRC Centre for Neuromuscular Diseases, University College London, London, UK.
Robinson PC; Rheumatology, University College London Centre for Rheumatology, London, UK.

Ann Rheum Dis ; 81(10): e191, 2022 10.

Article em En | MEDLINE | ID: mdl-32796043

Assuntos

Doenças Autoimunes; Tratamento Farmacológico da COVID-19; Médicos; Doenças Reumáticas; Reumatologia; Anticorpos Monoclonais Humanizados; Ensaios de Uso Compassivo; Hospitalização; Hospitais Gerais; Humanos; Agentes de Imunomodulação; Sistema de Registros; Doenças Reumáticas/complicações; Doenças Reumáticas/tratamento farmacológico

Palavras-chave

ankylosing; arthritis; lupus erythematosus; rheumatoid; spondylitis; systemic

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Médicos / Reumatologia / Doenças Autoimunes / Doenças Reumáticas / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google